Abstract:Transforming growth factor-β (TGF-β) is the primary factor that drives fibrosis in most, if not all, forms of chronic kidney disease (CKD). However, direct targeting of TGF-β is unlikely to be therapeutically feasible due to the involvement of TGF-β in other systems, including the immune system. Hence, the aim of this study was to identify Sirtuin 2 (SIRT2) as an endogenous regulatory of TGF-β signaling and renal fibrosis. In current study, we demonstrated that SIRT2 was downregulated in the renal tubules of patients with CKD and DKD, as well as a mouse model of renal fibrosis. In kidneys that are obstructed, specific deletion of Sirt2 in renal tubule epithelial cells (TEC) were shown to substantially aggravate renal fibrosis, and renal tubule specific overexpression of Sirt2 was sufficient to ameliorate renal fibrosis. Additionally, we showed that SIRT2 overexpression and knockdown restrained and enhanced TGF-β-induced fibrotic gene expression, respectively, in TEC. Mechanistically, SIRT2 reduced the phosphorylation, nuclear localization, and protein levels of SMAD2, leading to inhibition of the TGF-β signaling pathway. Further studies found that SIRT2 was able to directly interact with and deacetylate SMAD2 on lysine 451 and promote its ubiquitination and degradation. The mutation of lysine 451 to arginine in SMAD2 blocks the regulatory effect of SIRT2. Notably, loss of SMAD specific E3 ubiquitin protein ligase 2 abolished the ubiquitination and degradation of SMAD2 induced by SIRT2 in SMAD2. This study provides initial indication of the anti-fibrotic role of SIRT2 in renal tubules, suggesting its therapeutic potential for renal fibrosis.Funding Information: This work was supported by grants from the National Natural Science Foundation of China (82000824 to SY, 82170842 to ZL, 82171556 to LK), the Natural Science Foundation of Shenzhen City, China to ZL (No. KCXFZ20201221173600001), the National Key Research and Development Program of China (2018YFC2001100). Declaration of Interests: The authors have declared that no conflict of interest exists.Ethics Approval Statement: This study was approved by the Institutional Review Board and Ethics Committee of the Shenzhen People’s Hospital (approval no. LL-KT-2018338). Written informed consent was obtained from all participants prior to their inclusion in the study.All Animal care and experimental protocols for in vivo studies conformed to the Guide for the Care and Use of Laboratory Animals published by the National Institutes of Health (NIH; NIH publication no.:85–23, revised 1996) and were approved by the Ethics Committee of the Second Clinical Medical College of Jinan University, Shenzhen People’s Hospital (Shenzhen, China).

The Deacetylase Sirtuin 6 Protects Against Kidney Fibrosis by Epigenetically Blocking Β-Catenin Target Gene Expression.

Phosphorylation by GSK-3β increases the stability of SIRT6 to alleviate TGF-β-induced fibrotic response in renal tubular cells

Sirt6 deficiency exacerbates podocyte injury and proteinuria through targeting Notch signaling

Sirt6 Alleviated Liver Fibrosis by Deacetylating Conserved Lysine 54 on Smad2 in Hepatic Stellate Cells

Loss of Proximal Tubular Sirtuin 6 Aggravates Unilateral Ureteral Obstruction-Induced Tubulointerstitial Inflammation and Fibrosis by Regulation of β-catenin Acetylation

Overexpressed SIRT6 Attenuates Cisplatin-Induced Acute Kidney Injury by Inhibiting ERK1/2 Signaling

Sirtuin-6 inhibits cardiac fibroblasts differentiation into myofibroblasts via inactivation of nuclear factor κB signaling.

Nuclear Translocation of SIRT4 Mediates Deacetylation of U2AF2 to Modulate Renal Fibrosis Through Alternative Splicing-mediated Upregulation of CCN2

Sirtuin 6 protects against podocyte injury by blocking the renin-angiotensin system by inhibiting the Wnt1/β-catenin pathway

Minichromosome maintenance 6 protects against renal fibrogenesis by regulating DUSP6-mediated ERK/GSK-3β/Snail1 signaling

SIRT2 Alleviated Renal Fibrosis by Deacetylating SMAD2 and SMAD3 in Renal Tubular Epithelial Cells.

Sirtuin 6 Protects Cardiomyocytes from Hypertrophy in Vitro Via Inhibition of NF‐κB‐dependent Transcriptional Activity

SIRT2 Alleviated Renal Fibrosis by Deacetylating Conserved Lysine 451 on SMAD2 in Renal Tubular Epithelial Cells

SIRT6 protects vascular smooth muscle cells from osteogenic transdifferentiation via Runx2 in chronic kidney disease

Overexpression of Sirtuin 6 suppresses cellular senescence and NF-κB mediated inflammatory responses in osteoarthritis development

Endothelial SIRT6 Is Vital to Prevent Hypertension and Associated Cardiorenal Injury Through Targeting Nkx3.2-GATA5 Signaling

SIRT6 Protects Against Endothelial Dysfunction and Atherosclerosis in Mice

Sirt6 ameliorates high glucose-induced podocyte cytoskeleton remodeling via the PI3K/AKT signaling pathway

Renal Fibrosis: SIRT1 Still of Value

The sirtuin SIRT6 blocks IGF-Akt signaling and development of cardiac hypertrophy by targeting c-Jun

STAT6 contributes to renal fibrosis by modulating PPARα-mediated tubular fatty acid oxidation